Key takeaways
- GHK-Cu is one of five compounds the TGA gave in April 2026 to illustrate unapproved peptide products, a group it says is “often supplied in injectable form”.
- Under the Therapeutic Goods Act 1989, a product presented for a therapeutic use is a therapeutic good, and one not included in the ARTG is unapproved.
- The TGA says it does not assess cosmetics unless they make therapeutic claims; cosmetic ingredients are regulated as industrial chemicals under the Industrial Chemicals Act 2019.
- The October 2026 Poisons Standard does not name GHK-Cu, though it has group entries for copper compounds; separately, the TGA says supplying unapproved peptide products is unlawful.
- Neither the 2026 nor the 2027 WADA List names GHK-Cu, and Sport Integrity Australia, which counts it among unapproved peptide products, says many of those are prohibited in sport.
01Is GHK-Cu a therapeutic good or a cosmetic in Australia?
It depends on the product, not the molecule. Australian law sorts products by how they are presented and what they are for.
Therapeutic goods. The Therapeutic Goods Act 1989 covers goods represented as being for “therapeutic use”, which includes “influencing, inhibiting or modifying a physiological process in persons”. The TGA’s peptide products page, last updated on 23 September 2026, says a peptide product is regulated as a therapeutic good if, for example, it is “promoted, supplied or generally used for a therapeutic purpose”. Section 19B of the Act makes it an offence to import or supply therapeutic goods for use in humans that are not registered, listed, exempt or approved.
Cosmetics. The same TGA page says: “Some peptide products may be regulated as cosmetics rather than a therapeutic good if their ingredients, claims, presentation and intended use are limited to cosmetic purposes.” The TGA’s cosmetics page adds: “We do not assess cosmetics unless they make therapeutic claims. The ingredients in cosmetics are regulated as industrial chemicals.” That scheme sits under the Industrial Chemicals Act 2019 and is run by the Australian Industrial Chemicals Introduction Scheme (AICIS).
What counts as a cosmetic. Section 9 of that Act defines a cosmetic as a substance or preparation placed in contact with an external part of the body to clean it, perfume it, change its appearance, keep it in good condition, protect it or alter its odours. The definition excludes “a therapeutic good within the meaning of the Therapeutic Goods Act 1989”. An injectable product falls outside it, since the definition covers external parts of the body.
Labels do not decide it. The TGA says “research use only” disclaimers alone do not “change a product’s regulatory status”. More: what “research use only” means.
| How the product is presented and used | Regime | Who regulates |
|---|---|---|
| An injectable vial, or any product presented for a therapeutic use. | Therapeutic good; unapproved unless included in the ARTG. | TGA (Therapeutic Goods Act 1989, ss 3 and 19B). |
| A skin product whose ingredients, claims, presentation and intended use are limited to cosmetic purposes. | May be regulated as a cosmetic, the TGA says; cosmetic ingredients are regulated as industrial chemicals. | AICIS for ingredients; the ACCC for labelling and product safety, the TGA says. |
| Any product labelled “research use only”. | The label alone does not change the status. | TGA. |
| Any product containing a copper compound. | Poisons Standard group entries for copper compounds may apply. | States and territories, which give the Standard effect. |
| Use by athletes in sports under the Code. | WADA Prohibited List. | Sport Integrity Australia. |
02What has the TGA said about GHK-Cu?
TGA documents in 2026 mention GHK-Cu in two ways: as a named example, and inside a laboratory test.
13 April 2026. The TGA’s safety advisory on unapproved peptides gives its examples: “Examples of unapproved peptide products include those containing BPC‑157, GHK‑Cu, TB‑500, retatrutide and CJC‑1295, often supplied in injectable form.” The same advisory states that under the Act “peptide products are regulated as therapeutic goods in Australia”.
5 November 2026. TGA laboratory testing of products from one brand, identified with NSW Police, covered two blends labelled as containing GHK-Cu with other peptides. The TGA reported no detectable TB-500 in either. It did not report a GHK-Cu result. In the same alert it said that “most peptide products, including BPC-157, TB-500 and melanotan I, are prescription-only medicines in Australia”.
23 September 2026. The TGA’s peptide products page set out the cosmetic route quoted above. It does not name GHK-Cu.
Sport Integrity Australia’s peptides page also gives GHK-Cu as one of its examples of unapproved peptide products.
03Is GHK-Cu in the Poisons Standard?
Not by name. On 18 November 2026 we searched the full text of the October 2026 Standard (F2026L01327) for “GHK”, “copper tripeptide”, “prezatide” and “glycyl-L-histidyl” and found no entry.
Scheduling is not approval. The Poisons Standard sets supply controls; the Therapeutic Goods Act decides whether a product may be supplied at all. And in the TGA’s view, any dealing in unapproved peptide products, from import and advertising to manufacture and supply, is unlawful.
The copper group entries. The Standard does schedule copper compounds as a group. Schedule 4, prescription-only medicines, lists “COPPER COMPOUNDS for human use”, with exceptions when separately specified, for internal preparations at or below a stated copper content, and for other preparations at or below a stated percentage. Schedule 6, poisons, lists “COPPER COMPOUNDS” with similar exceptions, plus exceptions for certain pigments and feed additives.
GHK-Cu is a copper(II) complex. Whether a group entry captures a given GHK-Cu product would turn on the product and its copper content. We found no TGA statement applying either entry to GHK-Cu, and we do not make that call here.
04What changed in 2026?
No law naming GHK-Cu changed. What changed is how actively the TGA polices peptides, and how plainly it describes the cosmetic route.
| Date | TGA action |
|---|---|
| 13 Apr 2026 | Safety advisory gives GHK-Cu as one of five examples of unapproved peptide products. |
| 7 May 2026 | Warns that poorly labelled peptide imports will not be released, and that it will notify the Australian Border Force to seize and destroy them. |
| 10 Jun 2026 | Adds unapproved peptide products to its compliance priorities. |
| 20 Jul 2026 | Says peptide products are being advertised online for purposes that include cosmetic ones, and that labelling a blank vial counts as manufacture. |
| 17 Aug 2026 | States: “It is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia.” |
| 23 Sep 2026 | Updates its peptide products page, including when a peptide product may be regulated as a cosmetic. |
| 1 Oct 2026 | The October 2026 Poisons Standard commences. It has no entry for GHK-Cu. |
| 5 Nov 2026 | Reports testing of two blends labelled with GHK-Cu: no TB-500 detected, and no GHK-Cu result reported. |
For the wider Australian rules, including imports and compounding, see are peptides legal in Australia? and is BPC-157 legal in Australia?
05How is GHK-Cu treated in Australian sport?
We searched WADA’s 2026 and 2027 Prohibited Lists for “GHK”, “copper” and “tripeptide” and found no entry. Class S0 covers pharmacological substances not addressed elsewhere on the List that have “no current approval by any governmental regulatory health authority for human therapeutic use”. The List does not say whether GHK-Cu meets that test, and we have not checked its status with every regulator. The 2027 List adds “peptides” to the S0 examples, and WADA’s 2027 notes say an unnamed peptide “may still be prohibited”.
Sport Integrity Australia gives GHK-Cu as an example of an unapproved peptide product. It says “Many unapproved peptides are prohibited in sport” and that a therapeutic use exemption “is unlikely to be granted for an unregistered medicine”. How S0 applies to a given product is for the anti-doping organisation to decide, so athletes should check with Sport Integrity Australia. More: peptides and anti-doping.
06What we don’t know
Whether the copper group entries reach GHK-Cu. No TGA statement we found applies them to it.
Its AICIS status. We did not check whether copper tripeptide-1 is on the Australian Inventory of Industrial Chemicals; the inventory search needs a browser.
The ARTG. We could not search it, since the TGA site timed out for us. We know of no entry.
Enforcement involving GHK-Cu. The TGA’s releases describe seizures and notices by product type, not by compound.
State and territory rules. Poisons laws differ by jurisdiction, and we have not summarised them.
For the research on GHK-Cu, see our GHK-Cu research guide, GHK-Cu on the skin and peptides in skincare. Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.